Company / R&D per Share
MoonLake Immunotherapeutics R&D per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.15
FY2025
5-year range
$0.65 / $4.53
FY2021-FY2025
Trend
+75.4%
vs FY2024
Sector context
#66 of 208
Health Care
What the data says
At $3.15, MoonLake Immunotherapeutics's r&d per share ranks #66 of 208 in the Health Care sector. Improved from $0.65 to $3.15 over the past 2 years.
Based on SEC 10-K filings.
3.15 in FY2025 with a 3-year CAGR of +30.0%.
Improved from $0.65 to $3.15 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +30.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#66 of 208 in Health CareTop 32% of 208This company $3.15 Sector average $28.82
▼
-89.1% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 75.4% year-over-year.
- Ranks #66 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
- Lowest r&d per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.15 | +75.4% |
| FY2024 | $1.79 | +177.1% |
| FY2023 | $0.65 | -54.8% |
| FY2022 | $1.43 | -68.4% |
| FY2021 | $4.53 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026